|
US1362062A
(en)
|
1920-02-16 |
1920-12-14 |
American Sanitary Works |
Water-closet bowl
|
|
US2882777A
(en)
|
1955-11-03 |
1959-04-21 |
Leland Gifford Co |
Hydraulic tracing apparatus
|
|
US3233920A
(en)
|
1963-02-27 |
1966-02-08 |
Mueller Co |
Insulated pipe joint
|
|
US4518584A
(en)
|
1983-04-15 |
1985-05-21 |
Cetus Corporation |
Human recombinant interleukin-2 muteins
|
|
US5116943A
(en)
|
1985-01-18 |
1992-05-26 |
Cetus Corporation |
Oxidation-resistant muteins of Il-2 and other protein
|
|
US5206344A
(en)
|
1985-06-26 |
1993-04-27 |
Cetus Oncology Corporation |
Interleukin-2 muteins and polymer conjugation thereof
|
|
US6967092B1
(en)
|
1996-10-25 |
2005-11-22 |
Mc Kearn John P |
Multi-functional chimeric hematopoietic receptor agonists
|
|
US6955807B1
(en)
|
1998-05-15 |
2005-10-18 |
Bayer Pharmaceuticals Corporation |
IL-2 selective agonists and antagonists
|
|
US6348192B1
(en)
|
1999-05-11 |
2002-02-19 |
Bayer Corporation |
Interleukin-2 mutein expressed from mammalian cells
|
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
|
EP1454138B1
(en)
|
2001-12-04 |
2012-01-18 |
Merck Patent GmbH |
Immunocytokines with modulated selectivity
|
|
WO2004021861A2
(en)
|
2002-09-03 |
2004-03-18 |
Vit Lauermann |
Targeted release
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
WO2005007121A2
(en)
|
2003-07-18 |
2005-01-27 |
Massachusetts Institute Of Technology |
Mutant interleukin-2(il-2) polypeptides
|
|
ES2432141T3
(es)
|
2005-01-27 |
2013-11-29 |
Novartis Vaccines And Diagnostics, Inc. |
Procedimientos para tratar carcinoma de células renales
|
|
US9931413B2
(en)
|
2005-04-06 |
2018-04-03 |
Ibc Pharmaceuticals, Inc. |
Tetrameric cytokines with improved biological activity
|
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
|
WO2007001677A2
(en)
|
2005-05-17 |
2007-01-04 |
University Of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
ATE537190T1
(de)
|
2006-06-02 |
2011-12-15 |
Regeneron Pharma |
Hochaffine antikörper gegen den humanen il-6- rezeptor
|
|
PT2170959E
(pt)
|
2007-06-18 |
2014-01-07 |
Merck Sharp & Dohme |
Anticorpos para o receptor humano de morte programada pd-1
|
|
GB0815216D0
(en)
*
|
2008-08-21 |
2008-09-24 |
Asterion Ltd |
Interleukin
|
|
WO2010085495A1
(en)
|
2009-01-21 |
2010-07-29 |
Amgen Inc. |
Compositions and methods of treating inflammatory and autoimmune diseases
|
|
RU2583876C2
(ru)
|
2009-08-17 |
2016-05-10 |
Роше Гликарт Аг |
Иммуноконъюгаты направленного действия
|
|
US8734774B2
(en)
|
2010-04-02 |
2014-05-27 |
University Of Rochester |
Protease activated cytokines
|
|
CU23923B1
(es)
|
2010-11-12 |
2013-07-31 |
Ct De Inmunología Molecular |
Polipéptidos derivados de la il-2 con actividad agonista
|
|
WO2012088446A1
(en)
|
2010-12-22 |
2012-06-28 |
Board Of Trustees Of The Leland Stanford Junior University |
Superagonists and antagonists of interleukin-2
|
|
CN105440123B
(zh)
|
2011-02-10 |
2020-10-09 |
罗切格利卡特公司 |
突变体白介素-2多肽
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
PL3351261T3
(pl)
|
2011-10-11 |
2021-12-06 |
Universität Zürich |
Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów
|
|
US9156897B2
(en)
|
2012-06-08 |
2015-10-13 |
Alkermes, Inc. |
Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide
|
|
US9580486B2
(en)
|
2013-03-14 |
2017-02-28 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of T-regulatory cells
|
|
SG11201509595PA
(en)
|
2013-05-28 |
2015-12-30 |
Dcb Usa Llc |
Antibody locker for the inactivation of protein drug
|
|
TWI681969B
(zh)
*
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
GB2527075A
(en)
|
2014-03-17 |
2015-12-16 |
Daassist As |
Percutaneous system, devices and methods
|
|
MA40094B1
(fr)
*
|
2014-08-06 |
2022-05-31 |
Univ Miami |
Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
|
|
WO2016025647A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
|
|
IL304950A
(en)
|
2015-04-10 |
2023-10-01 |
Amgen Inc |
Interleukin for the expansion of myotonic control T-2 cells
|
|
MX383464B
(es)
*
|
2015-07-13 |
2025-03-14 |
Cytomx Therapeutics Inc |
Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos.
|
|
US20170204154A1
(en)
|
2016-01-20 |
2017-07-20 |
Delinia, Inc. |
Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
|
|
US11053293B2
(en)
|
2016-02-05 |
2021-07-06 |
Washington University |
Compositions and methods for targeted cytokine delivery
|
|
CN108697798A
(zh)
|
2016-02-16 |
2018-10-23 |
达纳-法伯癌症研究所有限公司 |
免疫疗法组合物及方法
|
|
US11291721B2
(en)
|
2016-03-21 |
2022-04-05 |
Marengo Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
|
US12202856B2
(en)
|
2016-05-19 |
2025-01-21 |
The General Hospital Corporation |
Tethered interleukin-2 to its receptor IL-2RBETA, a platform to enhance natural killer and regulatory T cell activity
|
|
KR102379464B1
(ko)
|
2016-06-20 |
2022-03-29 |
키맵 리미티드 |
항-pd-l1 항체
|
|
EP3538548A4
(en)
|
2016-11-08 |
2020-08-19 |
Delinia, Inc. |
IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
|
|
KR20240005989A
(ko)
|
2017-03-15 |
2024-01-12 |
큐 바이오파마, 인크. |
면역 반응을 조절하는 방법
|
|
BR112019018915A2
(pt)
|
2017-03-15 |
2020-04-14 |
Pandion Therapeutics Inc |
imunotolerância direcionada
|
|
CN107082812B
(zh)
|
2017-03-29 |
2018-11-13 |
上海科医联创生物科技有限公司 |
一种恢复衰竭性免疫细胞功能的融合蛋白及其应用
|
|
JP7148539B2
(ja)
|
2017-04-03 |
2022-10-05 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
免疫抱合体
|
|
KR102461885B1
(ko)
|
2017-04-03 |
2022-11-03 |
에프. 호프만-라 로슈 아게 |
항-pd-1 항체와 돌연변이 il-2 또는 il-15의 면역접합체
|
|
US20200362058A1
(en)
|
2017-05-24 |
2020-11-19 |
Novartis Ag |
Antibody-cytokine engrafted proteins and methods of use
|
|
AU2018273914A1
(en)
|
2017-05-24 |
2019-11-14 |
Pandion Operations, Inc. |
Targeted immunotolerance
|
|
US20210277085A1
(en)
|
2017-05-24 |
2021-09-09 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
WO2018226750A1
(en)
|
2017-06-06 |
2018-12-13 |
Relinia, Inc. |
Single-chain tnf receptor 2 agonist fusion proteins
|
|
AU2018287317B2
(en)
|
2017-06-19 |
2024-06-20 |
Medicenna Therapeutics Inc. |
Uses and methods for IL-2 superagonists, agonists, and fusions thereof
|
|
US20200306301A1
(en)
|
2017-07-03 |
2020-10-01 |
Torque Therapeutics, Inc. |
Polynucleotides Encoding Immunostimulatory Fusion Molecules and Uses Thereof
|
|
WO2019051127A1
(en)
|
2017-09-07 |
2019-03-14 |
Cue Biopharma, Inc. |
MULTIMER MODULATOR POLYPEPTIDE OF LYMPHOCYTE T HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
KR102777151B1
(ko)
|
2017-11-21 |
2025-03-05 |
더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 |
인터루킨-2의 부분 효능제
|
|
US10946068B2
(en)
|
2017-12-06 |
2021-03-16 |
Pandion Operations, Inc. |
IL-2 muteins and uses thereof
|
|
US10174091B1
(en)
|
2017-12-06 |
2019-01-08 |
Pandion Therapeutics, Inc. |
IL-2 muteins
|
|
EP3720871A4
(en)
|
2017-12-06 |
2021-09-15 |
Pandion Operations, Inc. |
TARGETED IMMUNOTOLERANCE
|
|
KR20240115352A
(ko)
|
2017-12-06 |
2024-07-25 |
팬디온 오퍼레이션스, 인코포레이티드 |
Il-2 뮤테인 및 그 용도
|
|
JP7765181B2
(ja)
|
2017-12-19 |
2025-11-06 |
ゼンコア インコーポレイテッド |
改変されたｉｌ－２ ｆｃ融合タンパク質
|
|
US11970537B2
(en)
|
2017-12-26 |
2024-04-30 |
Nanjing GenScript Biotech Co., Ltd. |
Fusion protein dimer using antibody Fc region as backbone and use thereof
|
|
MX387358B
(es)
*
|
2018-02-28 |
2025-03-18 |
Pfizer |
Variantes de il-15 y usos de las mismas
|
|
WO2019168791A2
(en)
|
2018-02-28 |
2019-09-06 |
The Board Of Trustees Of The Leland Stanford Junior University |
Single-chain il-2/antibody fusions that selectively activate regulatory t cells
|
|
CA3115461A1
(en)
|
2018-03-09 |
2019-09-12 |
AskGene Pharma, Inc. |
Novel cytokine prodrugs
|
|
PE20210313A1
(es)
*
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
|
CU24554B1
(es)
|
2018-05-07 |
2021-11-04 |
Ct Inmunologia Molecular |
Proteínas de fusión compuestas por una muteína de interleucina 2 e interferón tipo 1
|
|
US20210130430A1
(en)
|
2018-05-14 |
2021-05-06 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
|
MX2020012251A
(es)
|
2018-05-14 |
2021-04-28 |
Werewolf Therapeutics Inc |
Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
|
|
BR112020025287A2
(pt)
|
2018-06-25 |
2021-03-09 |
University Of Washington |
Projeto de novo de miméticos de interleucina potentes e seletivos
|
|
US12522640B2
(en)
|
2018-07-24 |
2026-01-13 |
BioNTech SE |
IL2 agonists
|
|
WO2020061142A1
(en)
|
2018-09-18 |
2020-03-26 |
Pandion Therapeutics, Inc. |
Targeted immunotolerance
|
|
CN112105634B
(zh)
|
2018-09-21 |
2024-03-12 |
信达生物制药(苏州)有限公司 |
新型白介素2及其用途
|
|
CA3114179A1
(en)
|
2018-09-28 |
2020-04-02 |
Pierre Fabre Medicament |
New immunocytokines for the treatment of cancer
|
|
WO2020070150A1
(en)
|
2018-10-02 |
2020-04-09 |
Philogen S.P.A |
Il2 immunoconjugates
|
|
EP3660039A1
(en)
|
2018-11-30 |
2020-06-03 |
Philogen S.p.A. |
Il2 immunoconjugates
|
|
CA3116188A1
(en)
|
2018-10-12 |
2020-04-16 |
Xencor, Inc. |
Pd-1 targeted il-15/il-15ralpha fc fusion proteins and uses in combination therapies thereof
|
|
EP3897746A4
(en)
|
2018-12-19 |
2022-10-26 |
Cue Biopharma, Inc. |
MULTIMERIC T LYMPHOCYTE MODULATING POLYPEPTIDES AND METHODS OF USE THEREOF
|
|
WO2020132136A1
(en)
|
2018-12-19 |
2020-06-25 |
Cue Biopharma, Inc. |
Multimeric t-cell modulatory polypeptides and methods of use thereof
|
|
EP3897690A4
(en)
|
2018-12-19 |
2022-09-28 |
Cue Biopharma, Inc. |
T LYMPHOCYTE MODULATOR MULTIMERIC POLYPEPTIDES HAVING CONJUGATION SITES AND METHODS OF USE THEREOF
|
|
CN113573782B
(zh)
|
2018-12-21 |
2025-12-16 |
Ose免疫疗法公司 |
针对人pd-1的双功能分子
|
|
SG11202111409YA
(en)
|
2019-05-20 |
2021-12-30 |
Cytune Pharma |
IL-2/IL-15Rßy AGONIST DOSING REGIMENS FOR TREATING CANCER OR INFECTIOUS DISEASES
|
|
AU2020279240A1
(en)
|
2019-05-20 |
2021-12-23 |
Pandion Operations, Inc. |
MAdCAM targeted immunotolerance
|
|
AU2020285636A1
(en)
|
2019-05-24 |
2021-11-04 |
Proviva Therapeutics (Hong Kong) Limited |
IL-2 compositions and methods of use thereof
|
|
JP7778571B2
(ja)
*
|
2019-06-05 |
2025-12-02 |
アッシャー バイオセラピューティクス， インコーポレイテッド |
免疫細胞機能をモジュレートするための変異体インターロイキン－２ポリペプチドと抗原結合分子の融合体
|
|
CA3143034A1
(en)
*
|
2019-06-14 |
2020-12-17 |
Cugene Inc. |
Novel interleukin-2 variants for the treatment of cancer
|
|
WO2020259536A1
(zh)
|
2019-06-24 |
2020-12-30 |
南京金斯瑞生物科技有限公司 |
单克隆抗体-细胞因子融合蛋白二聚体及其应用
|
|
KR20260089650A
(ko)
|
2019-07-12 |
2026-06-15 |
프로비바 테라퓨틱스 (홍콩) 리미티드 |
Il-2 조성물 및 이의 사용 방법
|
|
AU2020329933A1
(en)
|
2019-08-15 |
2022-03-24 |
Cytimm Therapeutics, Inc. |
Modified interleukin 2 (IL-2) polypeptides, conjugates and uses thereof
|
|
CN114728179A
(zh)
|
2019-08-19 |
2022-07-08 |
潘迪恩运营公司 |
利用pd-1激动剂的靶向免疫耐受
|
|
WO2021055568A1
(en)
|
2019-09-19 |
2021-03-25 |
Proviva Therapeutics (Hong Kong) Limited |
Il-2 compositions and methods of use thereof
|
|
BR112022009110A2
(pt)
|
2019-11-14 |
2022-07-26 |
Werewolf Therapeutics Inc |
Polipeptídeos de citocina ativáveis e métodos de uso destes
|
|
IL293978A
(en)
|
2019-12-20 |
2022-08-01 |
Regeneron Pharma |
New il2 agonists and methods of using them
|
|
WO2021168192A2
(en)
|
2020-02-21 |
2021-08-26 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with pd-1 agonists or il-2 muteins
|
|
US11981715B2
(en)
|
2020-02-21 |
2024-05-14 |
Pandion Operations, Inc. |
Tissue targeted immunotolerance with a CD39 effector
|
|
EP4172216A4
(en)
*
|
2020-06-24 |
2024-12-04 |
Medicenna Therapeutics, Inc. |
BIFUNCTIONAL SUPERKINE AND USES THEREOF
|
|
TWI815194B
(zh)
|
2020-10-22 |
2023-09-11 |
美商基利科學股份有限公司 |
介白素2-Fc融合蛋白及使用方法
|